There is good news for the patients suffering from the atrial fibrillation (AF). Now, such patients will be able to use some new options to treat their atrial fibrillation more efficiently.

Atrial Fibrillation (AF) is a medical condition of body wherein your body generates rapid and irregular heart rates. Such uneven heart rates, in turn, increase the risk of cardiac strokes. Despite which level of atrial fibrillation, you suffer from, you cannot vouch on all the current treatment options.

On account of the analysis of new research studies on the atrial fibrillation, we are aware of their causes. A new research study focused on the nascent genetic factors for the AF disorder in huge numbers. Also, it also focused on gene identification associated with cardiac health. This research study was led by the scientists from the Broad Institute of MIT. These scientists were accompanied by a research team from the Harvard, Massachusetts General Hospital and a team from Boston University School of Public Health.

The researchers involved in the study hope that their findings will pave the way for new drug development to treat the atrial fibrillation (AF). The research analysis marks their presence in Nature Genetics.

Patrick Ellinor conveys, “In atrial fibrillation, the upper chamber of the heart beats irregularly. The electrical chaos in this chamber is similar to what happens after you throw a handful of pebbles into a pond and waves crash into each other randomly.” Patrick Ellinor is a cardiologist at the Massachusetts General Hospital. He is also a medicine professor at the Harvard Medical School and an associate member at Broad Institute of MIT and Harvard.

Carolina Roselli concludes, “Our results provide a complete picture of the genomic basis of atrial fibrillation. I am very excited for our team to take these findings into the lab to learn more about the molecular mechanisms responsible for the disease.” Carolina Roselli is a reckoned computational biologist at the Broad’s Cardiovascular Disease Initiative.